REGENXBIO to Present at a Key Healthcare Event
REGENXBIO Inc. (Nasdaq: RGNX) has announced its upcoming presentation at a prominent healthcare conference. This annual event is known for bringing together key stakeholders in the healthcare and biotechnology sectors.
Presentation Highlights
The exciting presentation is scheduled for 10:30 a.m. PT on a Wednesday in early January 2026. The venue for this important gathering will be the Westin St. Francis in a major city known for its influence in healthcare innovation.
Webcast Availability
For those unable to attend in person, REGENXBIO will provide a live webcast of the presentation, which can be found in the Investors section of the company's official website. An archived version of the webcast will also be available for about a month following the live event, allowing investors and stakeholders to catch up on the insights shared.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO is a trailblazer in the biotechnology sector, focusing on harnessing the curative potential of gene therapy. The company has made significant strides in the realm of adeno-associated virus (AAV) gene therapy, positioning itself as a leader in the development of one-time medical solutions for rare and retinal diseases.
Innovative Treatments in Development
REGENXBIO's commitment to innovation is evident in its advanced pipeline of therapeutic candidates. Among the noteworthy advancements are RGX-202, aimed at treating Duchenne muscular dystrophy, and two therapies in collaboration with Nippon Shinyaku: clemidsogene lanparvovec (RGX-121) for MPS II and RGX-111 for MPS I. Another exciting development is surabgene lomparvovec (ABBV-RGX-314), intended for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy, created in partnership with AbbVie.
Impact on Patient Care
To date, thousands of patients have benefitted from treatments utilizing REGENXBIO's AAV platform, which includes recognition for treatments such as Novartis' ZOLGENSMA®. The therapeutic solutions being developed have the potential to transform healthcare delivery and improve the quality of life for millions of individuals facing rare diseases.
Keeping in Touch
The company encourages stakeholders and the public to stay updated on their advancements and presentations by visiting their official website, where more information can be found about their ongoing projects and the latest news in gene therapy applications.
Frequently Asked Questions
What is the purpose of REGENXBIO's presentation?
REGENXBIO's presentation aims to showcase their advancements in gene therapy and share insights about their innovative treatments in the pipeline.
When will the presentation take place?
The presentation is set for 10:30 a.m. PT on a Wednesday in early January 2026.
Where can I access the webcast of the presentation?
A live and archived webcast of the presentation will be available in the Investors section of REGENXBIO's official website.
What are some of the key treatments being developed by REGENXBIO?
REGENXBIO is developing several innovative treatments, including RGX-202 for Duchenne muscular dystrophy and RGX-121 and RGX-111 for MPS II and MPS I respectively.
How has REGENXBIO impacted patient care?
Through its AAV platform, REGENXBIO has treated thousands of patients and continues to work towards curative therapies that improve the lives of individuals with rare diseases.